Identification of novel antivirals inhibiting recognition of Venezuelan equine encephalitis virus capsid protein by the Importin α/β1 heterodimer through high-throughput screening

• Published in: Antiviral research 2018-03, Vol.151, p.8-19
• Main Authors: Thomas, David R., Lundberg, Lindsay, Pinkham, Chelsea, Shechter, Sharon, DeBono, Aaron, Baell, Jonathan, Wagstaff, Kylie M., Hick, Caroline A., Kehn-Hall, Kylene, Jans, David A.
• Format: Article
• Language: English
• Subjects: Antivirals; High-throughput screen; Importins; Quantitative microscopy; VEEV
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/j.antiviral.2018.01.007

Although the alphavirus Venezuelan equine encephalitis virus (VEEV) has been the cause of multiple outbreaks resulting in extensive human and equine mortality and morbidity, there are currently no anti-VEEV therapeutics available. VEEV pathogenicity is largely dependent on targeting of the viral capsid protein (CP) to the host cell nucleus through the nuclear transporting importin (Imp) α/β1 heterodimer. Here we perform a high-throughput screen, combined with nested counterscreens to identify small molecules able to inhibit the Impα/β1:CP interaction for the first time. Several compounds were able to significantly reduce viral replication in infected cells. Compound G281-1564 in particular could inhibit VEEV replication at low μM concentration, while showing minimal toxicity, with steady state and dynamic quantitative microscopic measurements confirming its ability to inhibit CP nuclear import. This study establishes the principle that inhibitors of CP nucleocytoplasmic trafficking can have potent antiviral activity against VEEV, and represents a platform for future development of safe anti-VEEV compounds with high efficacy and specificity. •A novel HTS strategy was designed to identify inhibitors of a host-virus interface critical for VEEV infection.•Inhibitors selectively targeted the VEEV capsid host: importin α/β1 interaction at low μM concentration.•Lead compounds possessed robust antiviral activity with minimal toxicity.•Results validate the principle that targeting the host-virus interface can identify selective antivirals.•This represents a strong base for future development of potent anti-VEEV agents.